ThisCART19A by Suzhou Fundamenta Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

ThisCART19A is under clinical development by Suzhou Fundamenta Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Standard bacterial test for raw, organic milk needs to be updated

Cornell food scientists show that a standard quality test used for raw, organic milk is insufficient for distinguishing between specific groups of bacteria, suggesting that

February 7, 2024

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 24, 2024

China accepts Innovent-HUTCHMED’s cancer therapy NDA

Share this article The companies sought approval for sintilimab and fruquintinib to treat advanced endometrial cancer. Credit: Fancy Studio / Shutterstock.com. The China National Medical

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.